ABIONYX Pharma announces its financial calendar for the year 2024

Regulatory News:

ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant apoA-I, today announces its financial calendar for 2024.

Events

Dates*

2023 Full-Year Results

Monday, March 11, 2024

Cash position and activity update for Q1 2024

Thursday, May 16, 2024

Cash position and activity update for Q2 2024

Thursday, August 22, 2024

2024 Half-Year Results

Thursday, September 26, 2024

Cash position and activity update for Q3 2024

Thursday, November 14, 2024

* indicative dates subject to change

About ABIONYX Pharma

ABIONYX Pharma is a next-generation biotech company focused on developing innovative medicines in diseases where there is no effective or existing treatment, even the rarest ones. The company expedites the development of novel therapeutics through an extensive expertise in lipid science and a differentiated apoA-I -based technology platform. ABIONYX Pharma is committed to radically improving treatment outcomes in sepsis and critical care.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240307659062/en/

The Abionyx Pharma Share Stock at the time of publication of the news with a fall of -1,50 % to 1,049EUR on Lang & Schwarz stock exchange (07. März 2024, 19:44 Uhr).